Current Status and Advances in Imaging Evaluation of Neoadjuvant Chemotherapy of Breast Cancer

doi:10.37015/AUDT.2021.190036

Abstract

Abstract:

It is particularly important to evaluate the efficacy of neoadjuvant chemotherapy (NAC) for breast cancer. This article reviews the current status and progress of imaging evaluations regarding the efficacy of NAC in women with breast cancer, including mammography, ultrasound (US), computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET-CT) and radiomics. Each imaging method has value for evaluating the efficacy of NAC for breast cancer, but certain defects and limitations. Therefore, the optimal selection will employ a combination of multiple imaging methods that will not only benefit patients but also avoid the unnecessary waste of medical resources.

Key words: Neoadjuvant therapy; Breast neoplasms; Mammography; Ultrasonography; Computed tomography; MRI; PET-CT

Yixin Hu, MD, Fei Li, MD, Jianhua Zhou, MD. Current Status and Advances in Imaging Evaluation of Neoadjuvant Chemotherapy of Breast Cancer. Advanced Ultrasound in Diagnosis and Therapy, 2021, 5(1): 18-25.

Figures/Tables 3

Figure 1

Figure 2

Figure 3

References

[1]	DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA Cancer J Clin 2019; 69:438-51.
[2]	P Wang, JF Li, WS Yue, WY Li, Luo Y. The correlation between traditional ultrasound features and the expression of estrogen receptor, progesterone receptor, human epidermal growth factor receptor-2, and Ki-67 in breast carcinoma. Advanced Ultrasound in Diagnosis and Therapy 2018; 2:173-77.
[3]	Buchholz TA, Lehman CD, Harris JR, Pockaj BA, Khouri N, Hylton NF, et al. Statement of the science concerning locoregional treatments after preoperative chemotherapy for breast cancer: a National Cancer Institute conference. J Clin Oncol 2008; 26:791-7.
[4]	Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 2014; 384:164-72.
[5]	Fisher ER, Wang J, Bryant J, Fisher B, Mamounas E, Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer 2002; 95:681-95.
[6]	Hafiz F, Choudhury T, Kamal M, Banu SG. The spectrum of pathological changes in breast cancer following neoadjuvant chemotherapy. Mymensingh Med J 2014; 23:272-80.
[7]	Fiorica JV. Breast cancer screening, mammography, and other modalities. Clin Obstet Gynecol 2016; 59:688-709.
[8]	Chagpar AB, Middleton LP, Sahin AA, Dempsey P, Buzdar AU, Mirza AN, et al. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy. Ann Surg 2006; 243:257-64.
[9]	Liu J, Li LL, Zhou SB, Wang B, Hu WY, Wu XM. The implication of mammographic changes before and after neo-adjuvant chemotherapy in breast cancer. Journal of Medical Imaging, 2006,16(6):572-574. doi: 10.3969/j.issn.1006-9011.2006.06.010. [In Chinese]
[10]	Huber S, Wagner M, Zuna I, Medl M, Czembirek H, Delorme S. Locally advanced breast carcinoma: evaluation of mammography in the prediction of residual disease after induction chemotherapy. Anticancer Res 2000; 20:553-8.
[11]	Kim YS, Chang JM, Moon HG, Lee J, Shin SU, Moon WK. Residual mammographic microcalcifications and enhancing lesions on MRI after neoadjuvant systemic chemotherapy for locally advanced breast cancer: correlation with histopathologic residual tumor size. Ann Surg Oncol 2016; 23:1135-42.
[12]	Shah SK, Shah SK, Greatrex KV. Current role of magnetic resonance imaging in breast imaging: a primer for the primary care physician. J Am Board Fam Pract 2005; 18:478-90.
[13]	Keune JD, Jeffe DB, Schootman M, Hoffman A, Gillanders WE, Aft RL. Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. Am J Surg 2010; 199:477-84.
[14]	Roubidoux MA, LeCarpentier GL, Fowlkes JB, Bartz B, Pai D, Gordon SP, et al. Sonographic evaluation of early-stage breast cancers that undergo neoadjuvant chemotherapy. J Ultrasound Med 2005; 24:885-95.
[15]	Singh G, Kumar P, Parshad R, Seith A, Thulkar S, Hosten N. Role of color Doppler indices in predicting disease-free survival of breast cancer patients during neoadjuvant chemotherapy. Eur J Radiol 2010; 75:e158-62.
[16]	Peintinger F, Kuerer HM, Anderson K, Boughey JC, Meric-Bernstam F, Singletary SE, et al. Accuracy of the combination of mammography and sonography in predicting tumor response in breast cancer patients after neoadjuvant chemotherapy. Ann Surg Oncol 2006; 13:1443-9.
[17]	Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14:1371-9.
[18]	Rim A, Chellman-Jeffers M. Trends in breast cancer screening and diagnosis. Cleve Clin J Med 2008; 75 Suppl 1: S2-9.
[19]	XM Chen, JY Zhong, ZM Hu, W Wei, WH Yin, LG Cui, et al. Trans-lymphatic contrast-enhanced ultrasound in combination with blue dye injection is feasible for detection and biopsy of sentinel lymph nodes in breast cancer. Advanced Ultrasound in Diagnosis and Therapy 2018; 2:94-100.
[20]	Amioka A, Masumoto N, Gouda N, Kajitani K, Shigematsu H, Emi A, et al. Ability of contrast-enhanced ultrasonography to determine clinical responses of breast cancer to neoadjuvant chemotherapy. Jpn J Clin Oncol 2016; 46:303-9.
[21]	Cao X, Xue J, Zhao B. Potential application value of contrast-enhanced ultrasound in neoadjuvant chemotherapy of breast cancer. Ultrasound Med Biol 2012; 38:2065-71.
[22]	Corcioni B, Santilli L, Quercia S, Zamagni C, Santini D, Taffurelli M, et al. Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy(). J Ultrasound 2008; 11:143-50.
[23]	Fujisawa T, Hirakata T, Yanagita Y, Iijima M, Horikoshi H, Takeuchi K, et al. The detection of pCR after PST by contrast-enhanced ultrasonography for breast cancer. Breast Cancer 2013; 20:75-82.
[24]	Chen M, Wang WP, Jia WR, Tang L, Wang Y, Zhan WW, et al. Three-dimensional contrast-enhanced sonography in the assessment of breast tumor angiogenesis: correlation with microvessel density and vascular endothelial growth factor expression. J Ultrasound Med 2014; 33:835-46.
[25]	Hayashi M, Yamamoto Y, Ibusuki M, Fujiwara S, Yamamoto S, Tomita S, et al. Evaluation of tumor stiffness by elastography is predictive for pathologic complete response to neoadjuvant chemotherapy in patients with breast cancer. Ann Surg Oncol 2012; 19:3042-9.
[26]	Evans A, Armstrong S, Whelehan P, Thomson K, Rauchhaus P, Purdie C, et al. Can shear-wave elastography predict response to neoadjuvant chemotherapy in women with invasive breast cancer? Br J Cancer 2013; 109:2798-802.
[27]	Jing H, Cheng W, Li ZY, Ying L, Wang QC, Wu T, et al. Early evaluation of relative changes in tumor stiffness by shear wave elastography predicts the response to neoadjuvant chemotherapy in patients with breast cancer. J Ultrasound Med 2016; 35:1619-27.
[28]	Tran WT, Childs C, Chin L, Slodkowska E, Sannachi L, Tadayyon H, et al. Multiparametric monitoring of chemotherapy treatment response in locally advanced breast cancer using quantitative ultrasound and diffuse optical spectroscopy. Oncotarget 2016; 7:19762-80.
[29]	Tadayyon H, Sannachi L, Gangeh M, Sadeghi-Naini A, Tran W, Trudeau ME, et al. Quantitative ultrasound assessment of breast tumor response to chemotherapy using a multi-parameter approach. Oncotarget 2016; 7:45094-111.
[30]	Sadeghi-Naini A, Papanicolau N, Falou O, Zubovits J, Dent R, Verma S, et al. Quantitative ultrasound evaluation of tumor cell death response in locally advanced breast cancer patients receiving chemotherapy. Clin Cancer Res 2013; 19:2163-74.
[31]	Moschetta M, Scardapane A, Lorusso V, Rella L, Telegrafo M, Serio G, et al. Role of multidetector computed tomography in evaluating incidentally detected breast lesions. Tumori 2015; 101:455-60.
[32]	Min XU, Jian-Song JI, Chen-Ying LU, Chen SZ. The efficacy of CT in the evaluation of the neoadjuvant chemotherapy in patients with primary breast cancer. Journal of Medical Imaging 2012
[33]	Marinovich ML, Houssami N, Macaskill P, Sardanelli F, Irwig L, Mamounas EP, et al. Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer Inst 2013; 105:321-33.
[34]	Cho N, Im SA, Park IA, Lee KH, Li M, Han W, et al. Breast cancer: early prediction of response to neoadjuvant chemotherapy using parametric response maps for MR imaging. Radiology 2014; 272:385-96.
[35]	Wu J, Gong G, Cui Y, Li R. Intratumor partitioning and texture analysis of dynamic contrast-enhanced (DCE)-MRI identifies relevant tumor subregions to predict pathological response of breast cancer to neoadjuvant chemotherapy. J Magn Reson Imaging 2016; 44:1107-15.
[36]	Waugh SA, Purdie CA, Evans AJ, Lerski RA, Mcghee H, Vinnicombe SJ, et al. Response to neoadjuvant chemotherapy assessed by magnetic resonance imaging (MRI) texture analysis compared with residual cancer burden (RCB) and tumor subtype in primary breast cancer. Cancer Research 2016; 76:
[37]	Bahri S, Chen JH, Mehta RS, Carpenter PM, Nie K, Kwon SY, et al. Residual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab. Ann Surg Oncol 2009; 16:1619-28.
[38]	Galons JP, Altbach MI, Paine-Murrieta GD, Taylor CW, Gillies RJ. Early increases in breast tumor xenograft water mobility in response to paclitaxel therapy detected by non-invasive diffusion magnetic resonance imaging. Neoplasia 1999; 1:113-7.
[39]	Park SH, Moon WK, Cho N, Song IC, Chang JM, Park IA, et al. Diffusion-weighted MR imaging: pretreatment prediction of response to neoadjuvant chemotherapy in patients with breast cancer. Radiology 2010; 257:56-63.
[40]	Wu LM, Hu JN, Gu HY, Hua J, Chen J, Xu JR. Can diffusion-weighted MR imaging and contrast-enhanced MR imaging precisely evaluate and predict pathological response to neoadjuvant chemotherapy in patients with breast cancer? Breast Cancer Res Treat 2012; 135:17-28.
[41]	Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006; 33:254-62.
[42]	Andrade WP, Lima EN Osório CA do Socorro Maciel M Baiocchi G Bitencourt AG, et al. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer? Eur J Surg Oncol 2013; 39:1358-63.
[43]	Wang Y, Zhang C, Liu J, Huang G. Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis. Breast Cancer Res Treat 2012; 131:357-69.
[44]	Schelling M, Avril N, N?hrig J, Kuhn W, R?mer W, Sattler D, et al. Positron emission tomography using [(18)F]Fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-95.
[45]	Gillies RJ, Kinahan PE, Hricak H. Radiomics: images are more than pictures, they are data. Radiology 2016; 278:563-77.
[46]	Crivelli P, Ledda RE, Parascandolo N, Fara A, Soro D, Conti M. A new challenge for radiologists: radiomics in breast cancer. Biomed Res Int 2018; 2018:6120703.
[47]	Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, et al. Intratumoral spatial heterogeneity at perfusion mr imaging predicts recurrence-free survival in locally advanced breast cancer treated with neoadjuvant chemotherapy. Radiology 2018; 288:26-35.
[48]	Braman NM, Etesami M, Prasanna P, Dubchuk C, Gilmore H, Tiwari P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI. Breast Cancer Res 2017; 19:57.
[49]	Drukker K, Li H, Antropova N, Edwards A, Papaioannou J, Giger ML. Most-enhancing tumor volume by MRI radiomics predicts recurrence-free survival "early on" in neoadjuvant treatment of breast cancer. Cancer Imaging 2018; 18:12.
[50]	Ha S, Park S, Bang JI, Kim EK, Lee HY. Metabolic radiomics for pretreatment (18)F-FDG PET/CT to characterize locally advanced breast cancer: histopathologic characteristics, response to neoadjuvant chemotherapy, and prognosis. Sci Rep 2017; 7:1556.